AtriCure grows sales by 21% in Q4
AtriCure (NYSE: ATRC) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.
Stay updated with breaking news from Sam Eiber. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AtriCure (NYSE: ATRC) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.
Abbott (NYSE: ABT) announced today that an FDA advisory committee ruled that the benefits of its TriClip outweigh the risks.
Edwards Lifesciences (NYSE: EW) shares dipped slightly today on fourth-quarter results that topped the consensus sales forecast.
Edwards Lifesciences (NYSE:EW) announced today that the FDA granted approval for its Evoque tricuspid valve replacement system.
Bloomberg reports that a court declined to grant a longer pause on the Apple Watch import ban as a result of patent litigation with Masimo.